Invalidity dossier

US 12576080

Use of varenicline for treating ocular conditions

Current assignee: Oyster Point Pharma Inc

Added 6/9/2026, 5:02:04 AM

Active provider: Google · gemini-2.5-flash

Got a demand letter citing US 12576080?

Paste the full letter into the analyzer. We extract every asserted patent (this one and any others), characterize the asserter, flag validity vulnerabilities, and draft a sample response letter your attorney can adapt.

Analyze a letter →

Generic sample response letter (PDF)

Generates a draft reply letter to a generic infringement claim citing this patent, using the analysis in this dossier. For a response tailored to a specific letter you received, use the demand letter analyzer instead. Sample only — not legal advice. Do not send without review by a licensed patent attorney.

Watchlist

Get alerted when this patent moves.

Email-only, free, anonymous. We'll notify you when US 12576080 gets a new lawsuit, a new PTAB proceeding, or a new dossier section. One-click unsubscribe from any alert.

Patent summary

Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.

✓ Generated

Here is a concise summary of US patent 12576080, based on the provided authoritative text and current searches:

Title: Use of varenicline for treating ocular conditions

Assignee: Oyster Point Pharma Inc

Inventors: Douglas Michael Ackermann, JR., James LOUDIN, Kenneth J. Mandell

Filing Date: April 3, 2025 [cite: Filing date 2025-04-03]

Issue Date: March 17, 2026 [cite: Publication date 2026-03-17]

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Independent Claims Overview:
The provided patent text, which is designated as the authoritative source, does not contain a "Claims" section with numbered claims. Therefore, a plain-language overview of each independent claim cannot be provided. The "SUMMARY OF THE INVENTION" and "DETAILED DESCRIPTION OF THE INVENTION" sections describe various embodiments of methods and pharmaceutical formulations, but these are not presented as formal, numbered claims.

CAFC 2026 Dockets Search:
A search of the CAFC 2026 dockets for patent number US12576080 did not return any scheduled cases or specific litigation related to this patent as of the current date.

Generated 6/9/2026, 5:02:24 AM